UTHR United Therapeutics Corporation

Simplify Asset Management Inc. recently acquired a new stake of 19,920 shares in United Therapeutics Corporation (NASDAQ:UTHR), valued at approximately $8.35 million, making it their 16th largest holding. Institutional ownership for UTHR is very high at 94.08%, with significant recent buys from major funds. United Therapeutics reported an EPS beat ($7.16 vs. $6.89) but a slight revenue miss, with its stock trading near $503, and analysts rating it a consensus "Moderate Buy."

An insider at United Therapeutics (UTHR) has sold shares valued at $11,572,963, according to a recent SEC filing. This transaction, dated December 29, 2025, is one of several insider share sales reported for the company in recent weeks. United Therapeutics Corporation is a pharmaceutical company that markets commercial therapies for pulmonary arterial hypertension and an oncology product.

Pacer Advisors Inc. reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 33.5% in the third quarter of 2025, selling 170,666 shares and retaining 339,071 shares valued at approximately $142.1 million. Insiders have also been net sellers recently, offloading 595,664 shares totaling about $273.1 million in the last 90 days. Despite slightly missing revenue estimates, United Therapeutics exceeded Q3 EPS forecasts with $7.16 per share, and analysts generally maintain a positive outlook with an average target price near $505.

S&P 500 futures are flat in premarket trading, with United Therapeutics and Intel showing lags. While the broader market remains steady, specific stocks like UiPath Inc. and CCC Intelligent Solutions Holdings Inc. are seeing positive movement in early trading.

Jan Malcolm, a Director at United Therapeutics Corp, sold 50 shares of the company on December 23, 2025. This transaction is part of a broader trend where insiders have sold shares and made no purchases over the past year. United Therapeutics Corp is currently considered significantly overvalued based on its GF Value.

United Therapeutics Director Jan Malcolm sold 50 shares of the company's stock on December 23rd for $25,606, reducing her stake by 10.64%. This follows a previous sale of 50 shares on December 11th. The company recently beat EPS estimates but missed revenue forecasts, though analysts remain largely bullish with a "Moderate Buy" consensus rating.